Priovant Therapeutics

Executive Summary

Priovant Therapeutics is a private, clinical-stage biotechnology company founded in 2021 and headquartered in Durham, North Carolina. The company is focused on developing novel, targeted oral therapies for severe autoimmune diseases. Its lead program is a selective TYK2 inhibitor, a promising target for conditions such as psoriasis, psoriatic arthritis, and lupus, where there is significant unmet need. Priovant's approach aims to provide efficacy with improved safety and tolerability compared to existing treatments. While the company has not disclosed specific financial details or pipeline stage, its focus on a validated target with multiple potential indications positions it as a notable player in the autoimmune space. The company is actively advancing its lead candidate through clinical trials, with upcoming data readouts expected to provide key inflection points.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 data readout for TYK2 inhibitor in psoriasis60% success
• Q4 2026Initiation of Phase 2 trial in psoriatic arthritis80% success
• Q2 2026Series B financing round70% success